Patients and medical experts met on Emory’s campus to discuss a little-known disease that impacts thousands of Americans.

The therapy targets CD19+ B cells, offering a new mechanism for managing this multiorgan fibroinflammatory disease.

The U.S. Food and Drug Administration (FDA) on Thursday approved Amgen Inc.’s AMGN Uplizna (inebilizumab-cdon) as the first and only treatment for adult patients with Immunoglobulin G4-related disease ...

The European Medicines Agency’s (EMA) human medicines committee (CHMP) has recommended extending the therapeutic indication ...

This review elucidates the central role of metabolic reprogramming in renal fibrosis associated with IgG4-related disease ...

Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related disease presented at EULAR 2025 Additional orphan designation underscores Sanofi commitment to advancing ...

SACQ patients were more likely to have higher IgG4 levels at baseline and a higher prevalence of the proliferative subtype. Similar relapse rates were observed between SACQ and SQCQ (serologically ...

Cholangiographic classification of IgG4-SC into 4 types based on stricture location is crucial to differentiate IgG4-SC from other biliary conditions. Characteristic findings on intraductal ...

Akeso Inc. (9926.HK) today announced that its proprietary next-generation humanized IgG4 monoclonal antibody targeting CD47, ligufalimab (AK117), has been granted Orphan Drug Designation (ODD) by the ...

Prostate involvement was first reported in IgG4-RD approximately 2 decades ago and comprises only 9.6% of cases.

Two main types of autoimmune pancreatitis (AIP) have been described: type 1, linked to IgG4-related disease, and type 2, associated with inflammatory bowel diseases. Recently, a third type has been ...